| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID3767: Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations |
|
Medicine details |
|
| Medicine name | toferson |
| Formulation | intrathecal |
| Reference number | 4375 |
| Indication | Treatment of amyotrophic lateral sclerosis (ALS) associated with a mutation of the superoxide dismutase 1 (SOD1) gene |
| Company | Biogen Idec Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2023 |
| NICE guidance | ID3767: Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations |